Skip to main content
. 2021 Dec 9;27:293–303. doi: 10.1016/j.omtn.2021.12.001

Figure 5.

Figure 5

USP28 binds to miR-655-3p and promotes lenvatinib resistance of HCC

(A) A schematic drawing showing the putative binding sites of miR-655-3p with USP28. (B) The luciferase activity of luc-USP28 or mutant luc-USP28 in HCCLM3 cells after co-transfection with miR-655-3p. (C) USP28 mRNA expression in PLC/PRF/5 and HCCLM3 cells was modified by miR-655-3p mimic transfection. (D) USP28 protein expression in PLC/PRF/5 and HCCLM3 cells was modified by miR-655-3p mimic transfection. (E) miR-655-3p expression in PLC/PRF/5 and HCCLM3 cells was modified by miR-655-3p mimic transfection. (F) USP28 mRNA expression in PLC/PRF/5 and HCCLM3 cells was modified by circMED27 shRNA transfection. (G) USP28 protein expression in PLC/PRF/5 and HCCLM3 cells was modified by circMED27 shRNA transfection. (H) USP28 mRNA expression in PLC/PRF/5 and HCCLM3 cells was modified by shRNA transfection. (I) USP28 protein expression in PLC/PRF/5 and HCCLM3 cells was modified by shRNA transfection. (J) Reduced USP28 expression in PLC/PRF/5 and HCCLM3 cells increased their sensitivity to lenvatinib. (K) pVEGFR1–3 protein expression in PLC/PRF/5 and HCCLM3 cells was modified by circMED27 shRNA transfection. The data are represented as the mean ± SD. ∗p < 0.05; ∗∗p < 0.01; NS, not significant.